We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FINAL GUIDANCE COVERS HANDLING OF BA, BE TESTING SAMPLES
FINAL GUIDANCE COVERS HANDLING OF BA, BE TESTING SAMPLES
May 28, 2004
The FDA has issued a final guidance on how drugmakers and others should handle reserve testing samples used in bioavailabilty (BA) and bioequivalence (BE) studies that support new and generic drug applications, while citing past lapses in the rules governing drug testing samples.